300436 Fujian Cosunter Pharmaceutical
- 15.87
- +0.66+4.34%
Fujian Cosunter Pharmaceutical News
Guangshengtang (300436.SZ) reported 2023 annual results, with a net loss of 349 million yuan, an increase in year-on-year losses
Guangshengtang (300436.SZ) released its 2023 annual report. The company achieved operating income of 4.2 during the reporting period...
More Unpleasant Surprises Could Be In Store For Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Shares After Tumbling 28%
To the annoyance of some shareholders, Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) shares are down a considerable 28% in the last month, which continues a horrid run for the company. For
Guangshengtang (300436.SZ): Obtaining a patent certificate or authorization notice for a new drug under development
Gelonghui, April 3 | Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (“Guangsheng Zhonglin”), an innovative pharmaceutical holding subsidiary of Fujian Guangshengtang Pharmaceutical Co., Ltd., has actively carried out patent applications on a global scale to provide intellectual property protection for innovative drug research and development since starting innovative drug research and development. Recently, Guangsheng Zhonglin obtained the following patent certificates or authorization notices for new drugs under development. The compounds and morphology of the company's hepatitis B core protein inhibitor GST-HG141 (generic name: nericavir) have applied for international patents through the PCT channel, and have been exhausted up to now
Guangshengtang (300436.SZ): The total amount involved in the proposed termination of some technical service contracts is RMB 25.613 million
Gelonghui, March 31 | Guangshengtang (300436.SZ) announced that the company and Ruitailai signed a “technical service contract” for 10 drugs in March 2022. In addition to ritonavir tablets, clopidogrel bisulfate, aspirin tablets, and aspirin enteric tablets, this related transaction plans to prematurely terminate the “technical service contracts” for the remaining 7 drugs signed above and sign a “termination agreement”. The total amount involved in the termination of the related transaction agreement was 25.613 million yuan.
Guangshengtang (300436.SZ) subsidiaries obtained patent certificates or authorization notices for various innovative drugs
Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative pharmaceutical holding subsidiary...
Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Popularity With Investors Under Threat As Stock Sinks 25%
The Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) share price has fared very poorly over the last month, falling by a substantial 25%. For any long-term shareholders, the last month ends a
Guangshengtang (300436.SZ): Expected net loss of 260 million yuan to 298 million yuan in 2023
On January 30, Gelonghui | Guangshengtang (300436.SZ) announced that it expects net loss of 260 million yuan to 298 million yuan in 2023, deducting non-net loss of 248 million yuan to 286 million yuan, and operating income of 41 million yuan to 430 million yuan. During the reporting period, the company continued to invest in innovative drug research and development. The innovative drug GST-HG131 entered clinical phase II, GST-HG141 completed clinical phase II enrollment, and the anti-COVID-19 drug Taizhong was approved, achieving “zero breakthroughs” in the launch of innovative drugs. The company's R&D investment in 2022
Guangshengtang (300436.SZ): Thai Zhongding, an innovative anti-COVID-19 drug, has been successfully included in the scope of temporary health insurance payments
Gelonghui, January 19 | Guangshengtang (300436.SZ) said on the investor interactive platform that our innovative anti-COVID-19 drug, Thai Zhongding, has been successfully included in the scope of temporary medical insurance payments, paid in category B, and completed online registration in more than a dozen provinces and cities, including Beijing, Fujian, Hebei, and Shanghai. Currently, in order to deal with the risks posed by the COVID-19 variant JN.1, some provinces and municipalities have included Thai Zhongding in key drug reserve procurement. This is part of the normal sales and operation activities of enterprises, and there are no matters that should be disclosed but not disclosed.
Guangshengtang (300436.SZ) plans to establish Guangfu with Aotai Phase 9 to promote international business development
Guangshengtang (300436.SZ) announced that the company plans to invest in the 9th phase of the Fuzhou Aotai Investment Partnership (limited partnership) with the related party...
Guangshengtang (300436.SZ): Proposes to establish Guang Fulai, a holding subsidiary for export business
Gelonghui, January 9丨Guangshengtang (300436.SZ) announced that in order to implement the company's internationalization strategy, expand the international business field of the company's drugs, especially anti-coronavirus drugs, promote the development and growth of the international business scale and further enhance the company's comprehensive strength, Fujian Guangshengtang Pharmaceutical Co., Ltd. plans to jointly invest in the establishment of the relevant party Fuzhou Aotai Phase 9 Investment Partnership (Limited Partnership) (“Aotai Phase 9”) (“Aotai Phase 9” for short). Guangfulai's registered capital is RMB 50 million
Guangshengtang (300436.SZ): Plans to terminate the “Jiangsu ZTE Pharmaceutical Workshop Construction Project” and raise the remaining capital permanently to supplement working capital
Gelonghui, December 29丨Guangshengtang (300436.SZ) announced that the company held the 27th meeting of the 4th board of directors and the 24th meeting of the fourth board of supervisors on December 29, 2023 to review and pass the “Proposal on Terminating Some Fund-raising Investment Projects and Permanently Supplementing Liquidity”. In order to improve the efficiency of the use of raised funds and reduce the risk of capital raised investment, according to the actual progress of the company's fund-raising projects and changes in the market environment, the company agreed to “Jiangsu ZTE Formulation” in the fund-raising investment project to issue shares to specific targets “Workshop construction project” terminated
Guangshengtang (300436.SZ): GST-HG141, an innovative drug for the treatment of hepatitis B, completed the Phase II clinical trial plan and the number of cases enrolled
Gelonghui, December 29丨Guangshengtang (300436.SZ) announced that the innovative hepatitis B treatment drug GST-HG141 of Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative pharmaceutical holding subsidiary, has completed the enrollment of all infected patients planned in accordance with the requirements of the Phase II clinical plan. The hepatitis B core protein inhibitor GST-HG141 (Chinese generic name: Nerecovir, World Health Organization (WHO) International Non-Patent Name (INN): Neracorvir) is a new class of anti-hepatitis B virus drugs with a new target, which can inhibit the shelling and assembly of the HBV (hepatitis B virus) capsid.
Guangshengtang (300436.SZ): A class of innovative drugs, Thailand, will be included in temporary health insurance payments
Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative drug holding subsidiary...
Guangshengtang (300436.SZ): Solofovir tablets (progandine), the core drug for curing hepatitis C, obtained drug production registration approval
Gelonghui November 27丨Guangshengtang (300436.SZ) announced that recently, Fujian Guangshengtang Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” approved and issued by the State Drug Administration regarding the company's central drug for curing hepatitis C, solifosbuvir tablets (valgandine). The approval of solifosbuvir tablets for marketing and production will further improve the company's product layout in the field of liver health, strengthen its market share and leading position in the field of liver medicine, build the company's “liver disease expert” series brand, provide the company with new growth points, and help the company innovate, transform and develop.
Guangshengtang (300436.SZ) subsidiary's first-class innovative drug, Thai Zhongding (atetetevir tablets combined with ritonavir tablets), was approved for listing
Guangshengtang (300436.SZ) issued an announcement. On November 23, Fujian Guangshengzhong, the company's innovative drug holding subsidiary...
Guangshengtang (300436.SZ), a class of innovative drug, Taizhongding (atetetevir tablets in combination with ritonavir tablets), a new drug, was accepted
Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative drug holding subsidiary...
[BT Financial Report Instantaneous Analysis] Guangshengtang's 2023 Quarterly Report: Total assets increased, operating income continued to increase month-on-month, and net profit reduced losses
Earnings announcement time: 2023-10-28 00:10:14 Guangshengtang (stock code: 300436) is a listed company operating in the pharmaceutical manufacturing industry (C27). It is committed to providing scientific solutions for human liver health, promoting innovative drug research and development, and implementing innovative development strategies. The company mainly deals in nucleoside (acid) anti-hepatitis B virus drugs and hepatoprotective drugs, covering liver health fields such as hepatitis B, hepatitis C, fatty liver disease, liver fibrosis, and liver cancer. At the same time, the company is also actively expanding products in the fields of antiviral, cardiovascular, and men's health. In terms of assets and liabilities, Guangshengtang20
Guangshengtang (300436.SZ) released the first three quarter results, with a net loss of 196 million yuan
Guangshengtang (300436.SZ) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 2...
Koseido (300436.SZ): The disclosure period for the third quarter report has been postponed until October 30
GLONGHUI October 19丨Guangshengtang (300436.SZ) announced that it was originally scheduled to disclose the “Report for the Third Quarter of 2023” on October 24, 2023. In order to further improve the work related to report preparation and review, and ensure the quality of the report and the authenticity, accuracy and completeness of the information disclosure, after applying to the Shenzhen Stock Exchange, the company extended the disclosure period of the “Report for the Third Quarter of 2023” until October 30, 2023.
Guangseitang (300436.SZ): Currently, the company has no R&D in the fields of diabetes or diet drugs
Glonghui, Oct. 19, 丨 Guangshengtang (300436.SZ) said on the investor interactive platform that the company's innovative solid tumor drug GST-HG161 is a unique highly selective c-Met targeted inhibitor. It has completed the tolerability and safety observations of all subjects in the dose increase phase I trial. Overall safety is good, and multi-center expansion phase tests are being carried out. The study found that c-Met inhibitors may be effective not only for hepatocellular carcinoma, but also for gastrointestinal cancer, lung cancer, etc. Currently, the company is not involved in R&D in the fields of diabetes or diet drugs.
Analysis
Price Target
No Data
